MedTrace Logo

Qingre Huashi Granules Combined the Modified Dual Therapy for Helicobacter Pylori Infection

NCT05364619 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2022-10-18

No results posted yet for this study

Summary

This is an open-label, randomized controlled trial. The aim of the study is to evaluate the efficacy and safety of the Qingre Huashi Granules combined the modified dual therapy (or called high dose dual therapy) for Helicobacter pylori infection specifically in geriatric patients, compared with the bismuth containing quadruple therapy. A total of 160 eligible patients will be enrolled in 4 hospitals. The eradication rate, symptoms, and the adverse events will be recorded and analyzed.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Qingre Huashi Granules combined the modified dual therapy

Qingre Huashi Granules combined the modified dual therapy for 14 days

DRUG

Bismuth containing quadruple therapy

Bismuth containing quadruple therapy for 14 days

Sponsors & Collaborators

  • Peking University International Hospital

    collaborator OTHER

  • Beijing Geriatric Hospital

    collaborator OTHER

  • Beijing Changping Integrative Medicine Hospital

    collaborator UNKNOWN

  • Peking University First Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-05
Primary Completion
2024-12-01
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05364619 on ClinicalTrials.gov